Top PDF ‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?
‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?
... ‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice? Despite being a common feature in clinical practice and a major ...
3
Pharmacological management of type 2 diabetes: what's new in 2017?
... in type 1 diabetes than in T2D, although caution is also required in certain circumstances in T2D ...agencies, which may limit the use of this new pharmacological class in clinical ...risk ...
36
DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
... attractive treatment options for combination ...need for specific studies for instance in insulin-treated ...DPP-4i, which opposes to the stimulatory effect on glucagon secretion ...
37
Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.
... atorvastatin for several years who had recently (6 months ago) started taking ...this clinical case), which can but does not necessarily predispose to acute kidney injury (which was not the ...
15
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
... requirements for patients with confirmed calculated creatinine clearance that decreased below a specific level (this level varied across studies) and/or increases in serum ...24-week treatment period; it ...
9
Voglibose for prevention of type 2 diabetes mellitus.
... drug treatment is more expensive and might be associated with adverse events (mostly gastrointestinal symptoms with α-glucosidase inhibitors, although in today's study reported as mild to moderate)? This question ...
3
Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?
... Diabetes & Metabolism 40 (2014) S1-S3 Type 2 diabetes is among the most important and preva- lent chronic diseases, and any novel therapy that is able to address chronic hyperglycaemia is ...
3
Pharmacological prevention of type 2 diabetes.
... for the prevention of type 2 diabetes in high-risk individuals, especially those with IGT ...in clinical practice ...modern definition of IGT and studied ...
46
Type 2 diabetes mellitus and osteoarthritis
... metformin treatment at baseline and OA outcome during follow up (adjusted HR = ...the Clinical Practice Research Datalink; it did not find any evidence for a disease modifying osteoarthritic ...
12
Preventing and treating kidney disease in patients with type 2 diabetes
... hard clinical outcomes such as progression to ESRD or death of renal cause requires a long follow-up in large ...endpoints, which, however, may differ across RCTs ( Table 1 – 4 ...marker, for ...
19
Preventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?
... of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, Liège, ...the Diabetes Prevention Program (DPP) showed that withdrawal of metformin for 1-2 weeks ...
4
Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
... studies, which contrasts with the unexpected interest devoted to C-peptide almost a decade ago [147,148] ...crucial for renal function in the glomeruli and ...in, for example, ...
12
DPP-4 inhibitors in the treatment of type 2 diabetes.
... role for GLP-1 in the cardiovascular ...mice, which spontaneously develop atherosclerosis, diminished atherosclerotic lesion size and monocyte/macrophage recruitment to the vascular wall independent of ...
27
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.
... insulin for a majority of patients with ...to which it lowers the glucose level. [43] Available data from clinical trials with dulaglutide confirm that the compound lowers both fasting and ...
32
Treatment of type 2 diabetes.
... with type 2 ...in type 2 diabetes, as initial therapy or most often after secondary failure to oral drug ...daily practice should include not only patient's clinical ...
13
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
... account for the acute glucose‐lowering effect of metformin, chronic metformin‐induced AMPK activation might indirectly inhibit hepatic glucose production by increasing hepatic insulin ...sensitivity. For ...
51
Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
... 2.2 Clinical efficacy Changes in plasma glucose, insulin, and glucagon in relation to glycaemic response after a liquid meal tolerance test were analyzed during treatment with dual add-on of dapagliflozin ...
44
An integrated approach for the identification of predictive markers of type 2 diabetes
... need for more accurate assessment of the inputs and their consequences to health (Panagiotou, ...of type 2 diabetes ...compared for several parameters (clinical, biochemical ...
2
Vitamin D and type 2 diabetes mellitus: Where do we stand?
... Fig. 1. Molecular structures of (upper) vitamin D2 (ergocalciferol) and (lower) vitamin D3 (cholecalciferol). Either vitamin D2 or D3 can also be found in many pharmaco- logical supplements but, whatever the source of ...
8
The endocannabinoid system: a promising target for the management of type 2 diabetes.
... The treatment with rimonabant reduced obesity-associated hepatic steatosis and features of metabolic syndrome, especially dyslipidemia, in obese Zucker fa/fa rats ...with type 2 diabetes ...
49